Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 23, Issue 12, Pages 3016-3023
Publisher
Oxford University Press (OUP)
Online
2012-08-09
DOI
10.1093/annonc/mds170
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study
- (2012) Frédéric Amant et al. LANCET ONCOLOGY
- Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature
- (2011) Krystyna Serkies et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study
- (2010) Kristel Van Calsteren et al. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
- Breast Cancer During Pregnancy
- (2010) Elyce Cardonick et al. CANCER JOURNAL
- Breast cancer in pregnancy: Recommendations of an international consensus meeting
- (2010) Frédéric Amant et al. EUROPEAN JOURNAL OF CANCER
- Gynecologic Cancers in Pregnancy
- (2010) Frédéric Amant et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Neoadjuvant Chemotherapy with Paclitaxel Plus Platinum Followed by Radical Surgery in Early Cervical Cancer During Pregnancy: Three Case Reports
- (2010) K.-C. Chun et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin and Weekly Paclitaxel for the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) During Pregnancy
- (2010) Hatem A. Azim et al. Journal of Thoracic Oncology
- Taxanes for breast cancer during pregnancy: a systematic review
- (2009) O. Mir et al. ANNALS OF ONCOLOGY
- Cisplatinum and docetaxel for ovarian cancer in pregnancy
- (2009) Abdulrahim A. Rouzi et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy
- (2009) Daisuke Doi et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled Study
- (2009) Michael J. Halaska et al. Breast Journal
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
- (2009) Stephen Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly epirubicin in the treatment of gestational breast cancer (GBC)
- (2008) Fedro A. Peccatori et al. BREAST CANCER RESEARCH AND TREATMENT
- Paclitaxel and cisplatin in the treatment of metastatic non-small-cell lung cancer during pregnancy
- (2008) Jorge García-González et al. Clinical & Translational Oncology
- Cause-Specific Survival for Women Diagnosed With Cancer During Pregnancy or Lactation: A Registry-Based Cohort Study
- (2008) Hanne Stensheim et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
- (2008) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of CYP2D6 and CYP3A4 in the First Year of Life
- (2007) TN Johnson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
- (2007) Michele De Laurentiis et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy
- (2007) Jung Han Kim et al. LUNG CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started